Year: 2019

LAVAL, Quebec, and HEIDELBERG, Germany, Dec. 20, 2019 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced today that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).

Thank you for your continued commitment. We wish you and your family a happy holiday season and best wishes for a healthy New Year. See you in 2020 ?

• Jiangsu Hengrui Medicine secures exclusive rights to develop, manufacture, and commercialize NOV03 and CyclASol® in China.
• NOV03 (perfluorohexyloctane) is a first-in-class investigational drug with a novel mode of action to treat Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
• CyclASol® (0.1% cyclosporine A in EyeSol®) is an anti-inflammatory and immunomodulating investigational drug developed for the treatment of aqueous deficient DED.
• Novaliq is eligible to receive upfront and milestone payments of up to $165 million plus royalties

Christian Roesky, PhD, CEO of Novaliq was interviewed by Ehsan Sadri, MD, FACS, FAAO and discussed how to treat Dry Eye Disease in the future based on the pivotal clinical trial results of NOV03 and CyclASol

Heidelberg, Germany – September 10, 2019 – Novaliq is pleased to announce that it has been recognised in the finalist roster of the Clinical Trial of the Year at the 2019 Lifestars Awards^TM.

Based on the new pivotal clinical trial results of NOV03 and CyclASol which were presented at the ASCRS, rethinking DED treatment becomes a reality.

Christian Roesky discusses how the company is rethinking DED therapy

• Betaliq is developing ophthalmic ß-blockers for the treatment of glaucoma using Novaliq’s waterfree EyeSol® technology
• Betaliq successfully collected proceeds in a Series A round

Listen in to Bernhard Günther, founder of Novaliq, about the company’s trailblazing start and promising future

• Novaliq is recognized for its SEECASE clinical trial results of NOV03 demonstrating unprecedented sign and symptom improvements for Dry Eye Disease (DED) patients while offering an excellent safety profile
• NOV03 is potentially the first drug targeting the key underlying cause of evaporative DED, the leading reason for this undertreated disease that impacts visual function